Medical treatment of Marfan syndrome: a time for change

Williams, A., Davies, S., Stuart, A. G., Wilson, Dirk G. and Fraser, Alan Gordon 2007. Medical treatment of Marfan syndrome: a time for change. Heart 94 (4) , pp. 414-421. 10.1136/hrt.2006.109454

Full text not available from this repository.

Abstract

It is accepted practice to prescribe β-blockers in order to retard aortic dilatation and prevent aortic dissection and rupture in patients with Marfan syndrome. A critical review of the published pharmacological studies shows this practice to be based on limited evidence. The data from small clinical and experimental studies with surrogate end points suggest greater potential benefit from alternative drug regimens, and a recent experimental study showed that losartan may interrupt the mechanism of disease as well as deal with its functional consequences. It is now essential to perform large, collaborative, randomised controlled trials with clinical end points of new treatments in Marfan syndrome.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	BMJ Group
ISSN:	1355-6037
Last Modified:	10 Oct 2017 14:16
URI:	https://orca.cardiff.ac.uk/id/eprint/28280

Citation Data

Cited 48 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item